Literature DB >> 2895317

Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

W E Robinson1, D C Montefiori, W M Mitchell.   

Abstract

Two components of human serum enhance human immunodeficiency virus type 1 (HIV-1) infection and mask HIV-1 neutralising antibody activity. The first is heat-stable, unique to HIV-1 seropositive sera, and is removed by protein-A chromatography. The second is heat-labile and ubiquitous; it is found in normal serum and is removed by heating at 60 degrees C for 1 h or by treatment with cobra venom anticomplementary protein. Additionally, complement component C3 deficient serum lacks the labile activity although Clq deficient serum contains the labile factor. The data suggest that the two components are antibody and the alternative pathway of complement fixation. The mechanism of action does not involve an increase in either complement-mediated cytolysis or syncytium formation. The activity has been identified in 11 of 16 patients tested to date.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895317     DOI: 10.1016/s0140-6736(88)91657-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  110 in total

1.  Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys.

Authors:  N M Ferguson; C A Donnelly; R M Anderson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

2.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

3.  Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.

Authors:  P R Johnson; D C Montefiori; S Goldstein; T E Hamm; J Zhou; S Kitov; N L Haigwood; L Misher; W T London; J L Gerin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

4.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  New FDA drug approval policies and HIV vaccine development.

Authors:  W K Mariner
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

7.  CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4.

Authors:  N Thieblemont; N Haeffner-Cavaillon; A Ledur; J L'Age-Stehr; H W Ziegler-Heitbrock; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

8.  Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line.

Authors:  G S Gras; D Dormont
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

Authors:  Kristina von Kietzell; Tanja Pozzuto; Regine Heilbronn; Tobias Grössl; Henry Fechner; Stefan Weger
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.